Investors are thrilled with the results and the money that intismeran may bring in for Moderna in the future. CEO Stéphane Bancel is excited about the possibility for the treatment to also go beyond just melanoma, stating that, "We believe it will work everywhere Keytruda works."

If it does turn again, the question is how much more the stock could lose on top of this drop: in past market-wide downturns, how far did Moderna stock

Shares of Moderna have comfortably outperformed the broader market over the past year, surging 885% compared to the S&P 500 Index's ($SPX) 8.2% surge. Moreover, in 2026, the stock has risen by nearly 712.7%, also outpacing the SPX's 7.4% gain.

The stock has soared 650% this year, largely outperforming many tech giants, the stocks that have driven positive market performance in recent years. Moderna stock still may be far from its record high, but it is trading 60% above analysts' estimates. At today's levels, is Moderna ripe for a stock split? Let's find out.

Moderna surges on pre-earnings momentum, Pfizer dips after beating estimates and raising guidance, and Merck drops despite launching a new trial. When stock prices and headlines point in opposite directions across the sector,

Moderna (MRNA) stock surged 7.38% as quarterly revenue reached $1.3 billion, cancer trial results improved, and the company raised its 2026 revenue outlook.

The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.

Moderna came into this Q3 2026 report with a volatile reputation and a rich story stock label, yet the hard numbers just forced a reset. The share price jumped 5.3% to US$254.19 on the first full trading day after results,